Last reviewed · How we verify

Cornerstone Health Care, PA — Portfolio Competitive Intelligence Brief

Cornerstone Health Care, PA pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Combigan Two Times Daily (BID) Combigan Two Times Daily (BID) marketed Fixed-dose combination of alpha-2 adrenergic agonist and beta-blocker Alpha-2 adrenergic receptor; beta-1 and beta-2 adrenergic receptors Ophthalmology
Natalizumab (Tysabri) Natalizumab (Tysabri) marketed Monoclonal antibody; integrin antagonist α4β1 integrin (VLA-4) Immunology; Neurology; Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Cornerstone Health Care, PA:

Cite this brief

Drug Landscape (2026). Cornerstone Health Care, PA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cornerstone-health-care-pa. Accessed 2026-05-16.

Related